The chief executive of pharmaceuticals company Actavis had taken to the stage to address the salesforce at Allergan, one of his first big outings after his group had said it would buy the maker of injectable skin treatments for $70bn last year. But David Pyott, Allergan’s outgoing boss, had arranged a surprise initiation.